Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.9052W HIGH $17.40
Volume
288.69 K
Value Traded
4.83 M
Short % Float
21.59%
-0.93%Week
-18.89%1 Month
-28.45%3 Month
-24.32%6 Month
-36.01%5 Year
-36.01%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
404.61 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-126.57 M
Total Shares
54.17 M
Float Shares
25.25 M
Insiders
53.39%
Institutions
39.78%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
EIKN Catalyst Timeline
Dated clinical, regulatory and corporate events for Eikon Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Eikon Therapeutics, Inc.
132Total events
13Upcoming
10Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Oral PresentationPresentation
Eikon to participate in KOL event on PARP inhibitors in oncology hosted by Cantor Fitzgerald
▲Interim AnalysisEIK1001Trial
First interim analysis of TeLuRide-006 completed by DMC
advanced melanomasource ↗
◆Poster PresentationEIK1001Presentation
Poster presentation at ASCO 2026
Stage 4 Non-Small Cell Lung Cancersource ↗
▲Oral PresentationEIK1001Presentation
EIK1001 TeLuRide-005 data at ASCO 2026
non-small cell lung cancer (NSCLC)source ↗
●Oral PresentationEIK1003Presentation
ASCO 2026 presentation of EIK1003-001 data
advanced solid tumorssource ↗
●Poster PresentationEIK1005Presentation
Poster presentation at ASCO 2026
Advanced Solid Tumors, Including MSI-H or dMMR Tumorssource ↗
◆Poster PresentationEIK1003Presentation
Poster presentation at ASCO 2026
advanced solid tumorssource ↗
▲Full ResultsEIK1001Clinical Data
Updated efficacy and safety data presented at ASCO 2026
stage 4 NSCLCsource ↗
▲Full ResultsEIK1003Clinical Data
Updated monotherapy and initial combination data presented at ASCO 2026
advanced solid tumorssource ↗
●Trial InitiationEIK1005Trial
Phase 1/2 study of EIK1005 presented at ASCO 2026 (publication only)
advanced solid tumors, including MSI-H or dMMR tumorssource ↗
◆Oral PresentationEIK1001Presentation
Presentation of TeLuRide-008 data at ASCO 2026
Non-Small Cell Lung Cancersource ↗
◆Oral PresentationEIK1003Presentation
Presentation of EIK1003-001 data at ASCO 2026
Advanced Solid Tumorssource ↗
◆Oral PresentationEIK1005Presentation
Presentation of EIK1005 first-in-human data at ASCO 2026
Healthy Participantssource ↗
●AbstractEIK1001Presentation
Abstract published for TeLuRide-008 trial of EIK1001 in Stage 4 NSCLC
Non-Small Cell Lung Cancersource ↗
●AbstractEIK1003Presentation
Abstract published for EIK1003-001 trial of EIK1003 in advanced solid tumors
Advanced Solid Tumorssource ↗
●AbstractEIK1005Presentation
Abstract published for first-in-human study of EIK1005 in healthy participants
Healthy Participantssource ↗
◆Oral PresentationPresentation
CEO to participate in Bank of America Securities 2026 Global Healthcare Conference
●PublicationPresentation
Publication in Journal of Medicinal Chemistry on single molecule tracking
◆Interim AnalysisEIK1001Trial
Full interim data readout of non-squamous cohort and partial interim data readout of squamous cohort for EIK1001 Phase 2 trial
non-small cell lung cancersource ↗
◆Trial InitiationEIK1001Trial
Initiation of Phase 2/3 trial in combination with pembrolizumab and chemotherapy for stage 4 NSCLC
non-small cell lung cancersource ↗
▲AbstractEIK1005Presentation
Two abstracts accepted for ASCO on EIK1005 PK/PD and Trial-in-Progress
advanced solid tumorssource ↗
▲Oral PresentationEIK1003Presentation
EIK1003 Phase 1/2 data presented at ASCO 2026
Solid Tumorssource ↗
●PublicationPresentation
Publication of RUVBL1/2 inhibitor discovery in Journal of Medicinal Chemistry
MYC-driven cancerssource ↗
▲Enrollment CompleteEIK1001Trial
Phase 2 trial of EIK1001 in combination with pembrolizumab and chemotherapy for NSCLC fully enrolled
non-small cell lung cancersource ↗
▲Enrollment CompleteEIK1003Trial
Dose escalation completed for Cohorts 1A, 1B, and 1C of EIK1003 Phase 1/2 trial
breast, ovarian, prostate, or pancreatic cancersource ↗
▲First Patient DosedEIK1003Trial
First patient dosed in Phase 2 dose optimization trial of EIK1003
breast, ovarian, prostate, or pancreatic cancersource ↗
●Trial InitiationEIK1003Trial
Global site selection initiated for Cohort 1D of EIK1003 trial
breast or ovarian cancersource ↗
●Milestone PaymentEIK1003Corporate
Paid $5.0 million milestone to Impact Therapeutics for EIK1003 Phase 2 advancement
▲Enrollment CompleteEIK1001Trial
Completed enrollment in TeLuRide-005 Phase 2 trial of EIK1001
first-line treatment of stage 4 non-small cell lung cancersource ↗
▲Trial InitiationEIK1005Trial
Phase 1/2 trial in patients with malignant disease now underway
malignant diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How EIKN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-29 | EIK1001 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C47 / 100
Pipeline Score
$407M
Pipeline Value
Fair Value
Valuation Signal
7
Drugs Scored
1.0x
rNPV / MCap
Top 23%
Micro Cap(rank 153 of 660)
Percentile Rank
Eikon Therapeutics, Inc. carries a moderate pipeline score (47/100), with $1.4B risk-adjusted pipeline value, led by EIK1001 in Advanced Melanoma (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EIK1001 Small moleculeNCT06697301 | Advanced Melanoma | Phase 2 | RECRUITING | 740 | Dec 1, 2040 |
Clinical Trial Results
Readouts, endpoints and source filings for every EIKN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EIK1001 | stage 4 NSCLC | Phase 2 | 2026-05-30 | 72 participants with previously untreated stage 4 NSCLC received intravenous EIK1001 QW combined with standard of care pembrolizumab plus chemotherapy Q3W.Read More | Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical OncologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Column Group IV GP, LP10% Owner | Buy | 89,200 89,200 held | $11.56 | 09/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EIKN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0 % | 7.25 M | 555.55 K |
EIKN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EIKN ranks across every disease it competes in
Competitive Position is a premium feature
See how EIKN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEIKN News
EIKNEikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Eikon Therapeutics has appointed Dr. Ching-Pin Chang as Executive Vice President and Chief Scientific Officer. Dr. Chang brings over two decades of experience in academic medicine and drug discovery, previously leading cardiovascular research at Bristol Myers Squibb. His expertise is expected to significantly contribute to Eikon's innovative drug development efforts.
Read more →EIKNEikon Therapeutics to Participate in Investor Conferences in September 2026
Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced participation in two investor conferences in September 2026. CEO Roger M. Perlmutter and CFO Freddie Bowie will present at the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference. The company focuses on developing innovative oncology therapies to meet significant medical needs.
Read more →EIKNEikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Eikon Therapeutics will participate in a KOL event on August 20, 2026, hosted by Cantor Fitzgerald. CEO Roger M. Perlmutter will join Dr. Timothy A. Yap, an expert in PARP inhibitors, to discuss their therapeutic use in various cancers. The event aims to shed light on the current landscape and limitations of PARP inhibitors.
Read more →EIKN▲ +7%on this newsshared move
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics reported its Q2 2026 financial results, highlighting significant advancements in its oncology pipeline. The company announced seven abstracts accepted for the ESMO Congress, showcasing promising clinical data for EIK1001 and EIK1003. Eikon ended the quarter with a robust cash position of $531.2 million, enabling continued support for its clinical programs despite a net loss of $88.4 million.
Read more →EIKN▲ +5.1%on this newsshared move
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
Eikon Therapeutics has announced the selection of a 0.60 mg/m² dose for the TeLuRide-006 trial, which is part of an ongoing adaptive Phase 2/3 study of EIK1001 in patients with advanced melanoma. This decision follows a recommendation from the independent Data Monitoring Committee, indicating confidence in the trial's design and direction.
Read more →EIKNEikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
Eikon Therapeutics has appointed Dr. Johnny Bennett to its Scientific Advisory Board. Dr. Bennett, currently Vice President at Merck Research Laboratories, brings significant expertise in medicinal chemistry and drug discovery. His addition is expected to enhance Eikon's research priorities and strengthen its collaboration with Merck, particularly in oncology-focused drug development.
Read more →EIKN▲ +11%on this news
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
Eikon Therapeutics has initiated dosing in the TeLuRide-008 trial, evaluating EIK1001 for stage 4 Non-Small Cell Lung Cancer. This Phase 2/3 study combines EIK1001 with pembrolizumab and chemotherapy, aiming to enhance immune responses. The trial represents a crucial step in addressing the unmet needs of NSCLC patients, with EIK1001 showing promise in earlier studies.
Read more →EIKNEikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Eikon Therapeutics announced the acceptance of seven abstracts for the 2026 ESMO Congress in Madrid. The presentations will cover updates from their clinical pipeline, including data from ongoing Phase 1/2 and Phase 2 trials of various drug candidates targeting advanced cancers. This highlights Eikon's commitment to developing innovative therapies for unmet medical needs.
Read more →EIKN▲ +16.2%on this news· ran to +29% by day 1
Eikon Therapeutics to Join the Russell 3000® Index
Eikon Therapeutics, a late-stage clinical biopharmaceutical company, announced its inclusion in the Russell 3000 Index, effective June 26, 2026. This addition highlights Eikon's growth and commitment to developing innovative medicines for serious medical needs, particularly in oncology. The Russell 3000 Index represents a significant portion of the US equity market, providing a benchmark for investors.
Read more →EIKNEikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
Eikon Therapeutics has appointed Ma. Fatima D. Francisco as an independent director on its Board, effective June 15, 2026. Francisco, who has a notable background in leadership from Procter & Gamble, will also serve on the Compensation Committee. Her expertise is expected to enhance Eikon's efforts in developing innovative medicines for serious unmet medical needs.
Read more →EIKNQ2 Company Update June 2026 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and shou
Eikon's Q2 Company Update outlines the progress of its clinical pipeline and highlights upcoming milestones for 2026. The FDA has sanctioned the transition to a Phase 2/3 registrational trial, with EIK1001 demonstrating efficacy in preliminary trials. However, the company is facing significant net losses and requires additional funding to support continued operations. Risks also include potential development failures and legal complications that could impact their future prospects.
Read more →EIKNEikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics presented updated data on its clinical-stage programs at the 2026 ASCO Annual Meeting. The Phase 2 trial of EIK1001 in stage 4 NSCLC showed promising response rates and tolerability. Additionally, EIK1003 demonstrated safety and efficacy as a monotherapy and in combination with paclitaxel for advanced solid tumors, reinforcing the potential of Eikon's innovative therapies.
Read more →EIKNEikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
Eikon Therapeutics announced the acceptance of six abstracts for presentation at the 2026 ASCO Annual Meeting. These abstracts showcase clinical progress in their oncology pipeline, including trials for EIK1001, EIK1003, and EIK1005. The presentations will highlight both monotherapy and combination strategies aimed at optimizing treatment for advanced cancers.
Read more →EIKNEikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics reported its first quarter 2026 financial results, highlighting a strong cash position of $596 million and continued progress in its oncology pipeline. The company focuses on three key programs: EIK1001, EIK1003, and EIK1005, with significant data to be presented at the upcoming ASCO annual meeting. Despite a net loss of $83 million, Eikon remains optimistic about its clinical advancements and financial outlook.
Read more →EIKNEikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
Eikon Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a successful IPO that raised $381 million. The company completed enrollment in the Phase 2 TeLuRide-005 trial for EIK1001 in lung cancer. Despite significant net losses and rising expenses, Eikon is advancing its clinical programs and expects to fund operations into 2027.
Read more →EIKNEikon Therapeutics Announces Pricing of Upsized Initial Public Offering
Eikon Therapeutics has announced the pricing of its upsized initial public offering, offering 21,177,600 shares at $18.00 each. The offering is expected to generate approximately $381 million in gross proceeds. Eikon's common stock will begin trading on the Nasdaq under the ticker symbol 'EIKN' on February 5, 2026. The offering is subject to customary closing conditions.
Read more →EIKNEikon Therapeutics Announces the Election of David W. Meline to its Board of Directors
Eikon Therapeutics has elected David W. Meline as an independent director, effective November 23, 2025. Meline, former CFO at Moderna and Amgen, brings significant financial and operational expertise to the board. His appointment is expected to enhance Eikon's strategic growth as the company advances its drug discovery initiatives.
Read more →EIKNEikon Therapeutics to Present New Phase 2 Data on EIK1001 in First-Line Non-Small Cell Lung Cancer at ESMO 2025
Eikon Therapeutics will present new Phase 2 data on EIK1001 at the ESMO Congress 2025. The study evaluates EIK1001, a TLR7/8 co-agonist, in combination with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer. The results aim to demonstrate improved patient outcomes and support the progression to a Phase 2/3 trial.
Read more →EIKNEikon Therapeutics to Share Clinical Data and Program Updates at the 2025 ASCO Annual meeting
Eikon Therapeutics will present new clinical data and program updates at the ASCO Annual Meeting from May 30 to June 3, 2025. The presentations will include safety and efficacy data from their selective PARP1 inhibitor EIK1003 and updates on their other oncology programs. Eikon has also entered a collaboration with Merck for a clinical trial involving EIK1001.
Read more →About Eikon Therapeutics, Inc.
Headquarters230 HARRIET TUBMAN WAY, MILLBRAE, CA, 94030
BIOPHARMAWATCH ELITE PLUS
Trade the next EIKN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime